


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Compounds of the formula I



wherein

R<sup>1</sup> is H, OH, OA, CN, Hal, COR or CH<sub>2</sub>R,

R is OH, OA, NH<sub>2</sub>, NHA or NA<sub>2</sub>,

R<sup>2</sup> and R<sup>3</sup> are H or A,

A is an alkyl group with 1-10 atoms,

X is O or S,

Hal is F, Cl, Br or I


n is 2-6,

m is 1-4


p is 0, 1, 2, 3 or 4

and their salts, enantiomers, solvates, racemates and other mixtures of enantiomers.


2. (Original) Compounds according to claim 1, wherein R<sup>1</sup> is F or CN.
3. (Currently Amended) Compounds according to claim 1 ~~or claim 2~~, wherein R<sup>3</sup> is H.
4. (Currently Amended) Compounds according to claim 1 ~~one or more of the claims 1 to 3~~, wherein X is S or O.
5. (Currently Amended) Compounds according to claim 1 ~~one or more of the claims 1 to 4~~, wherein p is 0 or 1 or 2 or 3 or 4.
6. (Currently Amended) Indol derivatives according to claim 1 ~~one or more of the proceeding claims~~ selected from the following group of compounds I1 to I5:




I1




I2



I3



I4



I5

and their salts, solvates, enantiomers and racemates.

7. (Original) Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as pharmaceutical active compounds.
8. (Original) Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as ligands of the 5HT-Receptor.

9. (Original) Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as serotonin reuptake inhibitor.
10. (Original) Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates 5HT1A antagonists.
11. (Original) Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates for use in the control of diseases.
12. (Original) Pharmaceutical preparation characterized in that it contains at least one compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts or solvates.
13. (Original) Use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts or solvates for the production of a medicament.
14. (Original) Use of compounds according to Claim 1 and/or their physiologically acceptable salts or solvates, enantiomeres or recemates for the production of a medicament for the treatment of illnesses which can be influenced by the binding of the compound of formula I to the 5-HT receptors.
15. (Original) Use of compounds according to Claim 1 and/or their physiologically acceptable salts or solvates, enantiomeres or recemates for the production of a medicament for the treatment of illnesses of the central nervous system, in particular of mental disorders of the schizophrenia type and for the control of psychotic anxiety states.